Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19

• Status: Terminated
• Trial end date: 2021-09-28
• Target enrollment: 0
• Participant gender: All

Summary

The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo

Criteria

Inclusion Criteria:

• Hypertension in use of renin-angiotensin system inhibitors

• Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical presentation and chest CT.

• Symptoms onset < 96h

• Need for hospitalization

Exclusion Criteria:

• Heart failure

• Previous cerebrovascular disease

• Previous myocardial infarction

• Blood pressure > 180 x 100 mmHg

• Need for 3 or more anti-hypertensive classes

• Use os spironolactone

• Severe pulmonary disease

• Contraindication for using other anti-hypertensive classes (calcium channel blockers, hydralazine, diuretics or nitrates)